Related Experiment Video
Updated: Oct 11, 2026
Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis
Published on: August 1, 2019
Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer
K Mäkinen1, S Loimas, J Wahlfors
1Department of Surgery, Kuopio University Hospital, Finland. kimmo.makinen@kuh.fi
Background:
Despite of recent improvements in the treatment of many malignant diseases, pancreatic ductal adenocarcinoma is still a disease with an extremely poor prognosis with current modes of treatment. Gene therapy has been suggested as a novel approach also against pancreatic cancer. Previous studies have been carried out predominantly with immunodeficient animal models and with tumors growing in environments other than the pancreas. We have attempted to mimic a more clinically relevant situation and investigated suicide gene therapy strategy for experimental pancreatic cancer in animals with an intact immune system.
Methods:
We used herpes simplex virus thymidine kinase (HSV-tk) and ganciclovir (GCV) strategy in both in vitro and in vivo settings.
Results:
In vitro studies demonstrated that retro- as well as adenovirally transduced HSV-tk-positive DSL-6A/C1 rat pancreatic carcinoma cells were sensitive to low concentrations of GCV when compared with parental, nontransduced cells. In addition, a strong bystander effect was observed. In in vivo studies, subcutaneously transplanted HSV-tk-positive DSL-6A/C1 cells were killed after GCV treatment, whereas parental, HSV-tk-negative cells continued to grow and developed into ductal adenocarcinomas. In in vivo HSV-tk-transduced pancreatic tumors, GCV treatment caused tumor necrosis and the necrosis volume was significantly more extensive when compared with control groups.
Conclusions:
HSV-tk gene transfer followed by GCV treatment is efficient in killing pancreatic cancer cells in vitro, in a transduced subcutaneous tumor model, as well as in in vivo transduced pancreatic tumors using an immunocompetent animal model. These results highlight the potential of gene therapy to treat experimental pancreatic cancer.
Insights
Suicide gene therapy using herpes simplex virus thymidine kinase (HSV-tk) and ganciclovir (GCV) effectively eliminated pancreatic cancer cells in experimental models. This approach shows promise for treating pancreatic ductal adenocarcinoma, even in immunocompetent animals.
Area of Science:
- Oncology
- Gene Therapy
- Cancer Research
Background:
- Pancreatic ductal adenocarcinoma has a poor prognosis despite treatment advances.
- Gene therapy offers a novel approach for pancreatic cancer treatment.
- Previous studies used non-ideal animal models, necessitating clinically relevant research.
Purpose of the Study:
- To investigate the efficacy of suicide gene therapy for experimental pancreatic cancer.
- To mimic a clinically relevant scenario using immunocompetent animal models.
Main Methods:
- Utilized the herpes simplex virus thymidine kinase (HSV-tk) and ganciclovir (GCV) suicide gene therapy strategy.
- Conducted both in vitro and in vivo experiments with genetically modified pancreatic cancer cells.
Main Results:
- HSV-tk-transduced cells were sensitive to GCV in vitro, with a significant bystander effect observed.
- In vivo, GCV treatment eradicated HSV-tk-positive tumors in immunocompetent animals.
- GCV treatment led to extensive tumor necrosis in the in vivo model.
Conclusions:
- HSV-tk gene transfer followed by GCV treatment is effective against pancreatic cancer cells in vitro and in vivo.
- The study highlights the potential of gene therapy for treating experimental pancreatic cancer in a relevant animal model.
